スタチン療法とコレステロールの低下に関する薬剤学的研究
Daniel I Chasman1, David Posada, Lakshman Subrahmanyan
1Center for Cardiovascular Disease Prevention, Brigham and Women's Hospital, Harvard Medical School, Boston, Mass 02215, USA.
JAMA
|June 17, 2004
まとめ
HMG-CoA還元酵素遺伝子の遺伝的変異は,プラバスタチンの有効性を低下させる可能性があります. 特定の遺伝子変異を持つ個人は,このスタチン療法によって小コレステロールの減少が見られる可能性があります.
科学分野:
- 薬剤遺伝学 薬剤遺伝学について
- 脂質代謝についてです.
- 心血管遺伝学 心血管遺伝学
背景:
- 薬剤反応に影響を与える遺伝的変異は,治療の有効性に影響を与える可能性があります.
- 脂質代謝遺伝子の多形態化は,スタチンの有効性に影響を与える可能性があります.
研究 の 目的:
- 遺伝子変異がプラバスタチン治療に対する反応に影響を与えるかどうかを体系的に評価する.
- シングル・ヌクレオチド・ポリモルフィズム (SNPs) とプラバスタチンの有効性との関連を調査する.
主な方法:
- 10の候補遺伝子の148のSNPに対してプラバスタチンで治療を受けた1536人のDNAを分析した.
- 遺伝子変異と24週間にわたる脂質レベルの変化との関連を調べた.
主要な成果:
- HMG-CoA還元酵素遺伝子の2つの一般的なSNPは,プラバスタチンの有効性の低下と関連していた.
- ヘテロジゴスな個体は,ホモジゴスな個体と比較して,総コレステロールとLDLコレステロールの減少が著しく小さかった.
- HDLコレステロールの変化やベースラインの脂質レベルとの関連は見つかりませんでした.
結論:
- HMG-CoA還元酵素遺伝子の遺伝的変異は,プラバスタチンのコレステロール低下効果を低下させることができます.
- 特定のHMG-CoA還元酵素遺伝子変異を持つ個人は,プラバスタチン治療から利益が少なくなる可能性があります.
関連する概念動画
01:20Lipid-Lowering Drugs: Statins and Miscellaneous Agents
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
01:29Pharmacogenetics and Pharmacogenomics: Overview
Pharmacogenetics and pharmacogenomics examine how genetic factors influence an individual's response to drugs. While pharmacogenetics focuses on the impact of specific genetic variants on drug effects, pharmacogenomics takes a broader approach, studying how genetic variation across populations contributes to differences in drug responses. These fields aim to explain why individuals may experience varying levels of efficacy or adverse reactions to the same medication.Variability in drug...
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
01:27Pharmacogenetics of Drug Metabolism: Overview
Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
01:29Pharmacogenomics: Identification of New Drug Targets
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...